China Proteomics Market Research Report: Trends, Forecast & Opportunities (2026-2032)

China Proteomics Market Key Takeaways

• The China proteomics market was valued at USD 3.88 billion in 2025, to 4.21 billion in 2026, and is projected to reach USD 7.99 billion by 2032.
• The industry is projected to witness steady growth at a CAGR of 11.27% during 2026–2032.
• Reagents & consumables dominate the market with approximately 55% share in 2026.
• Drug discovery & development leads the application segment with approximately 45% share in 2026.
• The market is moderately fragmented, with the top 5 players collectively holding approximately 30% combined share.

China Proteomics Market Size and Outlook

The proteomics market in China was valued at USD 3.88 billion in 2025, to 4.21 billion in 2026, and is projected to reach USD 7.99 billion by 2032, advancing at a CAGR of 11.27%. This growth is anchored by China's mounting cancer burden and aging demographic; the National Central Cancer Registry of China projects that new cancer cases among adults aged 60 and above will rise 46% between 2015 and 2030, from 2.2 million to 3.2 million. Additionally, the consequent demand for protein biomarker discovery, protein expression analysis, and quantitative proteomics workflows across oncology and clinical proteomics applications directly expands the addressable base for proteomics instruments and services.

Government investment in life sciences research reinforces this trajectory. The National Natural Science Foundation of China (NSFC) allocated USD 5.84 billion in 2025 for basic research funding across life sciences and medical sciences, with the 2026 budget further raised, a year-on-year increase of 6.09%. This sustained public allocation accelerates proteome research and proteomics bioinformatics infrastructure at academic institutions, driving procurement of liquid chromatography-mass spectrometry (LC-MS) and high-throughput proteomics platforms.

Moreover, the China National Medical Products Administration (NMPA) approved 289 new drug applications in 2025, up from 228 in 2024. This regulatory pipeline, dominated by therapeutic biological products requiring biomarker validation and drug target identification, directly accelerates demand from pharmaceutical R&D and clinical proteomics segments. Furthermore, Thermo Fisher Scientific's 2024 acquisition of Olink, a provider of next-generation proteomic solutions, introduced advanced proximity-extension assay platforms into the China proteomics solutions market. Collectively, the convergence of escalating disease burden, state-backed research funding, accelerating drug approvals, and expanding proteomics workflow solutions positions this market for sustained double-digit opportunity growth through 2032.

Key Indicators

• According to China's National Bureau of Statistics (NBS), China's expenditure on basic research reached CNY 249.7 billion in 2024, growing 10.5% year-on-year, a funding base that directly sustains proteomics bioinformatics, protein characterization, and molecular biology research infrastructure at universities and government-affiliated research institutions.
• According to China's Center for Drug Evaluation (CDE/NMPA), 4,900 clinical trials were registered in China in 2024, a 13.9% increase from 2023, of which 2,539 (51.8%) were for innovative drugs, each requiring biomarker validation, drug target identification, and protein quantification workflows, directly expanding procurement of proteomics instruments and LC-MS platforms.
• According to the National Natural Science Foundation of China (NSFC), the 2026 Natural Science Fund budget was set at USD 6.19 billion, a 6.09% year-on-year increase, with life sciences and medical sciences among priority funding areas, sustaining demand for proteomics workflow solutions, proteome profiling, and multi-omics integration platforms at academic research centres.
• According to the WHO International Clinical Trials Registry Platform (ICTRP), China listed 7,100 clinical trials in 2024, surpassing the United States (6,000) to become the world's leading registrant, reinforcing structural demand for translational research services, proteomics analysis tools, and protein expression analysis capabilities across China's pharmaceutical and biotechnology sectors.

China Proteomics Market Scope

China Proteomics Market Growth Drivers

Surging Pharmaceutical R&D and Drug Discovery Activity Driving Demand for Proteomics Solutions in China

Surging pharmaceutical R&D and innovative drug development in China is the most significant structural forces expanding demand for proteomics analysis, protein biomarker discovery, and proteomics workflow solutions. As domestic companies shift from generic manufacturing toward first-in-class therapies, proteomics technologies become indispensable from drug target identification and lead optimization to preclinical validation. The value of licensing deals for assets originating from China increased more than tenfold between 2020 and 2024, from approximately USD 5 billion to over USD 50 billion, reaching roughly 30% of global licensing deal value, according to Nature Biotechnology, a scale of innovation requiring sustained investment in protein analysis technologies.

This growth translates directly into instrument and service procurement. Jiangsu Hengrui Pharmaceuticals allocated USD 1.143 billion to R&D in 2024, a 33.79% year-on-year increase, funding an expanded pipeline of oncology and biologics programmes that require protein expression analysis, quantitative proteomics, and proteogenomic workflows at every stage of target validation. This sustained investment in innovative drug development directly expands procurement of proteomics instruments, protein microarrays, and proteomics bioinformatics platforms across China's pharmaceutical sector.

Recent Trends

Rising Adoption of AI-Powered Proteomics Bioinformatics Platforms Transforming Protein Data Analysis Workflows in China

China's proteomics research and pharmaceutical sector is increasingly replacing manual, data-heavy protein analysis workflows with AI-powered proteomics bioinformatics platforms, a shift driven by the explosion of large-scale mass spectrometry datasets that traditional methods can no longer process efficiently. As experiments generate thousands of data files across multiple laboratories and instruments, researchers and pharmaceutical companies are turning to machine learning models to automate protein identification, quality control, and proteomics data analysis at scale, reducing turnaround time and improving reproducibility across drug discovery and clinical proteomics applications.

China-based institutions are actively innovating under this trend. In January 2025, the Westlake Center for Intelligent Proteomics, Hangzhou, published iDIA-QC in Nature Communications, an artificial intelligence model trained on 2,754 mass spectrometry files across 21 instruments, automating quality control of quantitative proteomics workflows, achieving an AUC of 0.97 for instrument performance detection. In January 2026, the same team published ProteoAutoNet, integrating robotics with machine learning to double the throughput of protein interaction analysis. As these tools scale into commercial proteomics bioinformatics services, they would fundamentally transform how protein data analysis is procured and delivered across China's life sciences sector.

China Proteomics Industry Opportunities and Challenges

Shortage of Cross-Disciplinary Proteomics Bioinformatics Talent Driving Demand for No-Code and Low-Code Proteomics Workflow Automation Platforms

China's rapid deployment of high-throughput proteomics systems has created a widening talent gap: laboratories generate large-scale protein datasets, but cross-disciplinary experts those who simultaneously understand proteomics biology, mass spectrometry instrumentation, and advanced coding languages such as Python and R remain critically scarce. Training staff to bridge all three disciplines is expensive and time-consuming, slowing translation of raw proteomics data into actionable research insights. This bottleneck constrains analytical throughput across China's growing network of proteomics laboratories, contract research organizations, and healthcare research centers, limiting the return on significant instrument investments already made.

This challenge is directly creating demand for no-code and low-code proteomics bioinformatics automation platforms that allow laboratory technicians to run complex protein data analysis workflows through visual, prompt-driven interfaces without writing code. For Instance, in April 2026, MGI Tech, Shenzhen, launched its Generative Lab Intelligence platform, a multi-omics and proteomics bioinformatics solution powered by the DeepSeek V3 large language model that enables processing and visualization of complex proteomics datasets through workflow-driven prompts. This directly eliminates the coding expertise barrier for laboratory teams and creates a commercially expanding market for automated proteomics workflow solutions across China's life sciences sector.

Segmentation Insights

Consumables-Centric Spending Keeps Reagents & Consumables at the Forefront of China's Proteomics Demand

Reagents & consumables account for approximately 55% of the China proteomics market, driven by their consumable-by-nature demand model every experiment requires fresh reagents, creating recurring procurement cycles across academic, clinical, and biopharma research settings. Immunoassay and chromatography reagents dominate within this segment, underpinned by China's state-backed expansion of proteomics infrastructure under the 14th Five-Year Plan (2021–2025).

In March 2024, Thermo Fisher Scientific opened a new biomanufacturing facility in Hangzhou, China described as a "one-stop service" platform reinforcing local supply of life sciences reagents and consumables critical to proteomics workflows. The uninterrupted throughput requirement across drug discovery and biomarker discovery pipelines ensures this segment sustains structural dominance as China's clinical research output scales. By product type the market is further segmented into the following sub-categories:

• Instruments and Equipment
• Reagents & Consumables
• Software & Informatics Tools
• Services

Drug Discovery & Development Emerges as the Largest Application Segment

Drug discovery & development holds approximately 45% of the proteomics industry in China by application, reflecting the country's accelerating biopharmaceutical pipeline. China's National Medical Products Administration (NMPA) approved a record 48 first-in-class innovative drugs in 2024, covering nearly 20 therapeutic areas, including oncology and neurological disorders, reach requiring protein-level characterization at multiple development stages, making proteomics tools structurally integral to drug development workflows. BGI Genomics, headquartered in Shenzhen, operates an end-to-end proteomics and multi-omics services platform built on high-precision mass spectrometry, supporting pharmaceutical drug discovery and translational research clients across China.

As China's biopharma sector deepens reliance on target identification and mechanism validation at the protein level, drug discovery will continue anchoring application-segment demand while personalized medicine and biomarker discovery expand their combined footprint. By application the market is further segmented into the following sub-categories:

• Drug Discovery & Development
• Clinical Diagnostics
• Agricultural & Food Science
• Fundamental & Academic Research
• Environmental Proteomics
• Others

China Proteomics Industry Competitive Landscape

The China proteomics industry exhibits a moderately fragmented structure, characterized by the presence of several global life science and analytical instrumentation companies alongside a growing number of domestic Chinese participants. The market is led by companies such as Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies, Inc., Bruker Corporation, and Merck KGaA. Collectively, these five companies account for approximately 30% of the China proteomics market, reflecting a moderately fragmented competitive landscape where no single participant holds a dominant position.

Major Players in the China Proteomics Industry

• Promega Corporation
• Bruker Corporation
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Danaher Corporation
• Roche Holding AG
• Thermo Fisher Scientific Inc.
• GE HealthCare Technologies Inc.
• Merck KGaA
• Others

China Proteomics Industry News and Recent Developments

2025: Minghui Pharmaceutical Signs USD 198.8 million Licensing Agreement with Qilu Pharmaceutical for B7-H3 ADC Development in Greater China

Minghui Pharmaceutical announced an exclusive licensing agreement with Qilu Pharmaceutical on May 9, 2025, granting Qilu rights to develop and commercialize MHB088C — a B7-H3-targeted ADC — across Greater China. Qilu pays RMB 280 million upfront, with total potential payments reaching USD 198.8 million including milestones and double-digit royalties. MHB088C has been evaluated in over 300 patients in Phase I/II trials.

Impact Analysis: A multi-indication ADC programme spanning 300+ patients requires continuous biomarker validation and protein target characterization, expanding procurement of clinical proteomics services across China's oncology drug development sector.

2025: Syncell Installs Microscoop Spatial Proteomics Platform at China's National Center for Protein Sciences, Establishing First China Distribution Channel

Syncell launched its Preferred Partner Network on April 24, 2025, naming Cold Spring Biotech as its China distributor alongside service partners OMAPiX and MS Bioworks for end-to-end spatial proteomics workflows. Simultaneously, Syncell's Microscoop a subcellular spatial proteomics platform was installed at the National Center for Protein Sciences, Beijing, China's largest proteomics research center, marking the instrument's first China deployment.

Impact Analysis: First China installation of a subcellular spatial proteomics instrument at the country's largest protein sciences center establishes a direct commercial channel for spatial proteomics instruments and proteomics services across China's academic and clinical research sector.

2026: ISBER, BBCMBA, and BGI Partner to Host the 2026 ISBER Annual Meeting & Exhibits in Shenzhen, China

The International Society for Biological and Environmental Repositories (ISBER), the Biobank Branch of China Medicinal Biotech Association (BBCMBA), and BGI announced a partnership to host the 2026 ISBER Annual Meeting in Shenzhen. The event will bring together global experts in biobanking, biospecimen management, precision medicine, and multi-omics research, strengthening international scientific collaboration and knowledge exchange within China's life sciences ecosystem.

Impact analysis: The collaboration reinforces China's position as a leading hub for biobanking and multi-omics research. As high-quality biospecimen repositories are critical for proteomics-based biomarker discovery and precision medicine, the event is expected to accelerate research partnerships, technology adoption, and investment in proteomics infrastructure, supporting long-term growth of the China proteomics market.